Published in Blood Weekly, January 15th, 2004
The results were presented at the American Society of Hematology annual meeting.
The interim analysis of the study's first 150 anemic cancer patients with a current diagnoses or history of a nonmyeloid malignancy shows that after 12 weeks of Aranesp treatment, the mean change in hemoglobin was 1.9 g/dL for the Aranesp group and 0.2 g/dL in the control group, which received standard care. The baseline...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.